No quarterly revenue total was found in Cingulate Inc.'s SEC filings.
Cingulate Inc. (CING) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$6.0 million. As of Jun 30, 2026 it held $28.4 million in cash and investments and $1.2 million in total debt.
Revenue
—
Net income
$-5.87M
-17.8% vs year-ago quarter
Operating cash flow
$-5.90M
-23.0% vs year-ago quarter
Free cash flow
$-5.97M
-22.5% vs year-ago quarter
EPS
$-0.45
+60.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
14.54M
+168.7% vs year-ago quarter
Net cash
$27.18M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CING (Nasdaq), CINGW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Kansas City, KS
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1862150
- Former names
- Cingulate Inc. (until Oct 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.4M | -$7.9M | -$5.6M | -$6.0M | -$4.6M |
| Net income | -$5.9M | -$9.3M | -$6.3M | -$7.3M | -$5.0M |
| Diluted EPS | -$0.45 | -$0.95 | -$0.93 | -$1.35 | -$1.14 |
| Operating cash flow | -$5.9M | -$6.9M | -$3.6M | -$4.2M | -$4.8M |
| Free cash flow | -$6.0M | -$7.0M | -$3.8M | -$4.2M | -$4.9M |
| Total assets | $33.1M | $30.9M | $15.1M | $10.5M | $13.5M |
| Total liabilities | $9.6M | $12.0M | $12.6M | $7.0M | $8.0M |
| Stockholders' equity | $23.5M | $18.9M | $2.5M | $3.5M | $5.5M |
| Cash and investments | $28.4M | $25.9M | $11.0M | $6.1M | $8.9M |
| Total debt | $1.2M | $1.3M | $1.3M | $1.4M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 2, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 23, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 14, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 2, 2026 | Jun 30, 2026 |
All 493 Cingulate Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.